Covidien and University of New South Wales to Collaborate on the Development of Novel Imaging Agent.License Agreement Brings Together Research Leaders in Pursuit of Apoptosis Detection Technology to Better Manage Medical Treatment of Cancer Patients SYDNEY, Aus. & ST. LOUIS -- NewSouth Innovations Pty Limited, the technology transfer arm of University of New South Wales The University of New South Wales, also known as UNSW or colloquially as New South, is a university situated in Kensington, a suburb in Sydney, New South Wales, Australia. (UNSW UNSW University of New South Wales (Australia) UNSW Unidentified Swallow UNSW United Nations Scholars' Workstation (Yale University) ), and Covidien Ltd. (NYSE NYSE See: New York Stock Exchange : COV COV Composés Organiques Volatiles (French) COV Compuestos Orgánicos Volátiles (Spanish: Volatile Organic Compounds) COV Coefficient of Variation COV City of Villians (game) , BSX BSX Bermuda Stock Exchange BSX Bandai Satellaview-X BSX Bicycle Super-X (Cross) : COV) today announced the signing of a license agreement to develop an innovative, radiolabeled molecular imaging agent for evaluating the efficacy of cancer treatments. This technology could assist oncologists in determining the effectiveness of treatment and the necessity for other therapeutic measures. Based in Sydney, Australia, UNSW is a leader in the field of adult cancer research with internationally recognized medical scientists. Covidien Imaging Solutions, which is based in St. Louis, Missouri (USA), is a leading provider of imaging products used by physicians to detect and diagnose various diseases. Under the exclusive, worldwide agreement, Covidien Imaging Solutions has product development and commercialization rights for this apoptosis technology, which was invented by Professor Philip Hogg hogg castrated male sheep usually 10 to 14 months old. Also used to describe an uncastrated male pig. , who is a co-director of the Lowy Cancer Research Centre. The family of small molecules developed by Professor Hogg is designed to bind to to contract; as, to bind one's self to a wife s>. See also: Bind cancer cells cells once believed to be peculiar to cancers, but now know to be epithelial cells differing in no respect from those found elsewhere in the body, and distinguished only by peculiarity of location and grouping. See also: Cancer undergoing apoptosis, or the process of cell death, as a result of chemotherapy treatment. "This discovery stems from more than 10 years of research focused on the design of molecular probes Molecular Probes is a biotechnology company located in Eugene, Oregon specializing in fluorescence. The company was founded in 1975 by Richard and Rosaria Haugland in their kitchen in Minnesota, then moved briefly to Texas and finally to Oregon in the early 1980s. to study cellular processes," said Professor Hogg. "These molecules are uniquely designed to attach to proteins inside cells undergoing apoptosis driven by chemotherapy." This early-stage apoptosis detection technology could take many years to develop, but it has the potential for broad application across a wide array of solid tumor cancers. According to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. data from the World Health Organization's International Agency for Research on Cancer The International Agency for Research on Cancer (IARC, or CIRC in its French acronym) is an intergovernmental agency forming part of the World Health Organisation of the United Nations. Its main offices are in Lyon, France. , there are approximately 11 million new cases of cancer worldwide each year. Along with helping doctors to assess therapeutic responses non-invasively, this apoptosis technology would support the movement toward personalized or targeted therapies based on a patient's specific needs. "This license agreement demonstrates Covidien's focus on technology that is intended to improve patient care," said Steve Hanley Steve Hanley is the name of:
In addition, pharmaceutical companies may use the apoptosis technology to evaluate new products for cancer treatment. Apoptosis-detecting imaging agents may also have applications outside of cancer, such as in neurological and cardiac disease following strokes and heart attacks. ABOUT COVIDIEN Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines, including Surgical Devices, Energy-Based Devices, Respiratory and Monitoring Solutions, Patient Care and Safety Products, Imaging Solutions, Pharmaceutical Products, Medical Supplies and Retail Products. With 2006 revenue of nearly $10 billion, Covidien has more than 43,000 employees worldwide in 57 countries, and its products are sold in over 130 countries. Please visit www.covidien.com to learn more about our business. ABOUT UNIVERSITY OF NEW SOUTH WALES The Sydney-based University of New South Wales (UNSW) is one of Australia's leading teaching and research universities. Ranked in the top 50 in the world, UNSW boasts close to 40,000 students and is recognized as a leader in the field of medical research. NewSouth Innovations Pty Limited (NSi), UNSW's technology transfer arm, specialises in transforming research and technology developed at UNSW into a successful venture or product. With more than 45 years' experience NSi evaluates research technologies, identifies appropriate collaboration opportunities and provides industry partners and investors with access to a wide range of technologies with broad commercial potential. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion